Hepatocellular carcinoma (HCC) represents one of the most significant health issues globally, given its high prevalence and challenging nature of liver physiology and hepatic surgery. This means that the most appropriate management of HCC should include a multidisciplinary approach, combining expertise from various specialties. This book showcases the steps involved in the development, diagnosis, staging, and management of HCC and provides us with the views and thoughts of true experts in the field. As such, it is a useful companion for any physician or surgeon, whether training or practicing, who is interested in caring for these patients.
Hepatocellular carcinoma (HCC) represents one of the most significant global health issues, given its high prevalence and the challenging nature and physiology of the liver and hepatic surgery, in its many forms. This means that the most appropriate management for HCC should incorporate a multidisciplinary approach, combining the expertise from several different specialties. This book showcases the various steps in the development, diagnosis, staging, and management of HCC and provides views and thoughts from true experts in the field. As such, it is a useful resource for any physician or surgeon, whether training or practicing, who is interested in caring for patients with HCC.
It is now widely accepted that multidisciplinary collaboration and multimodality treatment approaches are important in improving the survival of patients with hepatocellular carcinoma. In this comprehensive textbook, internationally renowned experts in the field present and discuss the various strategies employed in the treatment of the disease. Up-to-date information is provided on the indications for and outcome of a range of treatment options, including surgical resection, liver transplantation, radiofrequency ablation, transarterial chemoembolization, yttrium-90 transarterial radioembolization, and systemic therapy. In addition, important background information is included on biology, pathology, staging, and imaging. This book will be particularly helpful to all professionals and trainees worldwide who have an interest in the diagnosis and treatment of hepatocellular carcinoma.
Hepatocellular Carcinoma: Targeted Therapy provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options. This volume also provides an up-to-date guide for treatment that explores not only traditional treatments, but newer investigational treatment options including, surgical resection, liver transplantation, ablation (radiofrequency, microwave), percutaneous ethanol or acetic acid injection, transarterial chemoembolization (TACE), intra-arterial radiation therapy, and systemic chemotherapy. Heptocellular Carcinoma: Targeted Therapy will be of great value to all health care professionals and trainees worldwide who have an interest in the diagnosis and treatment of HCC, including surgeons, medical oncologists, radiologists, radiation oncologists, and pathologists.
The second edition of this book is intended as a definitive text on biliary tract and gallbladder cancers. Specifically, it will serve as a single-source reference on the current knowledge base for the multidisciplinary management of such cancers and thus covers epidemiological, surgical, radiotherapy, and chemotherapy approaches. A key feature is the demonstration of the impact of cutting-edge technical knowledge on treatment; for example, interventional radiology techniques, novel surgical approaches, and image-guided radiation therapy are all extensively discussed. Diagnosis is also considered in detail, with coverage of novel serum biomarkers, pathologic staging, molecular profiling, and the full range of current and emerging imaging strategies. This book will be an invaluable source of information on new techniques for experienced practitioners, yet is sufficiently concise to offer an introduction to the field for students and community practitioners.
This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models. The book is intended to assist collaboration between the diverse disciplines and facilitate forward and reverse translation between basic and clinical research by providing a comprehensive overview of relevant areas, covering epidemiological trend and population-level patient management strategies, new diagnostic and prognostic tools, recent advances in the standard care and novel therapeutic approaches, and new concepts in pathogenesis and experimental approaches and tools, by experts and opinion leaders in their respective fields. By thoroughly and concisely covering whole aspects of HCC care, Hepatocellular Carcinoma serves as a valuable reference for multidisciplinary readers, and promotes the development of personalized precision care strategies that lead to substantial improvement of disease burden and patient prognosis in HCC.
Hepatobiliary cancers, including hepatocellular carcinoma and biliary tract cancers, have high rate of mortality and low survival rate. The third volume of the “Interdisciplinary Cancer Research” series, entitled “Hepatobiliary Cancers: An Interdisciplinary Approach” publishes comprehensive volumes on mechanisms of hepatobiliary cancers and therapeutic modalities and presents the most updated and peer-reviewed chapters on hepatobiliary cancers. This interdisciplinary series is of special value to researchers working on cell biology, immunology, biochemistry, genetics, and practitioners working on oncology and gastroenterology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for researchers, oncologists, and gastroenterologists who wish to extend their knowledge on hepatobiliary cancers.
This comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options – radiological, surgical, pharmaceutical, and emerging/novel therapies – and help you find the best single or combined therapy. Building on the success of the previous edition, this extremely thorough revision: features a new section on Guidelines for Liver Tumors, where you will find specific strategies for treating common liver malignancies; the guidelines were prepared by the Associate Editors and take into account national and international society guidelines reflects actual practice by taking a multidisciplinary approach, with contributions from international experts who have extensive experience with this patient population achieves comprehensive and balanced coverage by having each chapter reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer includes 16 new chapters that cover liver anatomy, histologic changes in the liver, epidemiology and natural history of HCC, CCC and colorectal liver metastases, strategies of liver resection, and economic aspects as well as novel therapies facilitates the kind of daily interaction among hepatologists, hepatic surgeons, medical oncologists, radiotherapists, and interventional radiologists that is essential when treating patients with complex liver malignancies In 44 chapters organized into six major sections, the book covers the full range of liver tumors. The perfect blend of evidence and experience, Malignant Liver Tumors: Current and Emerging Therapies, 3rd Edition, illuminates the path to better patient care.
The incidence of primary and metastatic liver tumors is rising and the therapeutic armamentarium for these tumors is expanding at a rapid pace. Surgery remains the primary treatment modality for these tumors. With improvements in our perioperative management and operative techniques a larger proportion of patients are able to undergo potentially curative liver surgery. In addition, indications and criteria for liver transplantation for both primary and metastatic liver tumors are constantly expanding. Unfortunately, many patients are not amendable to surgical resection or liver transplantation and therefore alternative liver-directed therapies are routinely being implemented as part of complex multidisciplinary treatment models. However, these models are continually evolving as these regional therapeutic options continue to expand. New embolization agents and techniques, as well as, improvements in radiation delivery, are all evolving in the background of improvement in systemic and targeted therapy options for these tumors. This book provides a comprehensive, state-of-the art review of the current state of liver-directed therapy for malignant liver tumors. The book will serve as a valuable resource for not only surgeons and clinicians but for researchers with an interest in malignant liver tumors. The book focuses on the therapeutic approach to primary and metastatic tumors providing an up-to-date review on surgical liver anatomy and new imaging techniques as well as patient selection and technical consideration for resection and transplantation. In addition, the book provides new insight into novel and evolving therapies in the areas of transarterial therapy such as: (i) bland embolization, (ii) chemoembolization, and (iii) radioembolization; as well as new radiation techniques including SBRT and proton therapy. Furthermore, the expanding role of hepatic artery infusion therapy in primary malignant tumors is highlighted. Finally, integration of all these regional therapy options with upcoming and evolving systemic and targeted therapy regimens are integrated and discussed. This book will serve as a very useful resource for clinicians and researchers managing and treating patients with these challenging malignancies. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and include the most up to date scientific and clinical information.
